Shares of Apyx Medical Corporation (NASDAQ:APYX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.60.
APYX has been the topic of several research reports. Wall Street Zen lowered Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, HC Wainwright began coverage on shares of Apyx Medical in a research note on Monday. They set a “buy” rating and a $7.00 target price for the company.
View Our Latest Report on Apyx Medical
Apyx Medical Price Performance
Apyx Medical (NASDAQ:APYX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%.The firm had revenue of $12.49 million during the quarter, compared to analyst estimates of $10.53 million.
Institutional Trading of Apyx Medical
Hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC bought a new position in Apyx Medical in the 4th quarter valued at about $3,867,000. Huntleigh Advisors Inc. bought a new stake in shares of Apyx Medical during the 4th quarter worth about $827,000. Silverberg Bernstein Capital Management LLC raised its position in shares of Apyx Medical by 4.7% during the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 1,033,003 shares of the company’s stock worth $3,616,000 after buying an additional 46,500 shares in the last quarter. ExodusPoint Capital Management LP acquired a new stake in shares of Apyx Medical in the 4th quarter worth approximately $305,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Apyx Medical in the 4th quarter worth approximately $111,000. 55.33% of the stock is currently owned by institutional investors.
Apyx Medical Company Profile
Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.
Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.
Featured Articles
- Five stocks we like better than Apyx Medical
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
